Positive results for AstraZeneca’s asthma therapy
PT027 is being developed through a partnership involving AstraZeneca and Avillion
Read Moreby John Pinching | May 16, 2022 | News | 0
PT027 is being developed through a partnership involving AstraZeneca and Avillion
Read Moreby Selina McKee | Dec 21, 2017 | News | 0
Pfizer’s Bosulif has been approved in the US to treat patients with newly-diagnosed Ph+ chronic myelogenous leukemia.
Read Moreby Selina McKee | Mar 30, 2017 | News | 0
Merck has signed a collaboration agreement with the UK’s Avillion under which the latter will develop the German drug giant’s anti IL-17 A/F Nanobody as a treatment for plaque psoriasis.
Read Moreby Selina McKee | Dec 6, 2016 | News | 0
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis’ Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
